# TAU N279K Research Report

**Protein:** TAU N279K
**Variant:** N279K
**UniProt ID:** P10636
**Disease Association:** Alzheimer's disease
**Report Generated:** 2026-05-26 03:47 UTC
**AlphaFold Confidence (pLDDT):** 54.2%
**Structure Folded:** 2026-05-12

---

## Structure Summary

Tau is a brain protein that stabilizes the cellular scaffolding (microtubules) in neurons, but in Alzheimer's disease it forms toxic tangles that spread through the brain and correlate with cognitive decline. The N279K variant, which replaces a neutral amino acid with a positively charged one in tau's microtubule-binding region, is classified as pathogenic by expert panels and has never been observed in the general population, suggesting it directly causes disease. Structural modeling of this variant shows extremely low confidence (average 54.2 out of 100), reflecting tau's naturally disordered structure, which makes it prone to the abnormal folding and aggregation seen in Alzheimer's disease.

---

The tau protein (MAPT gene) normally binds to and stabilizes microtubules, the transport highways inside neurons that are essential for moving cargo throughout these long cells. In Alzheimer's disease and related dementias, tau becomes hyperphosphorylated (decorated with phosphate groups), detaches from microtubules, and aggregates into neurofibrillary tangles that spread systematically through the brain [1]. The density and distribution of these tangles correlates strongly with cognitive decline, making tau a central therapeutic target [1][4].

The N279K variant replaces asparagine (a polar, neutral amino acid) with lysine (a positively charged amino acid) at position 279, located within tau's microtubule-binding repeat region. This variant is classified as pathogenic by multiple expert submitters in ClinVar based on established criteria, and critically, it has never been observed in gnomAD, a database cataloging genetic variation in over 140,000 individuals from diverse populations. The complete absence in healthy populations combined with pathogenic classification strongly indicates this variant directly causes disease rather than being a benign polymorphism. Disease-causing MAPT variants are well-documented to cause frontotemporal dementia and parkinsonism, with molecular mechanisms including altered tau phosphorylation, increased aggregation propensity, and disrupted microtubule binding [2][5].

Structural modeling using AlphaFold2 predicts N279K tau with an average confidence score (pLDDT) of 54.2, which is extremely low by structural biology standards. However, this low confidence is expected and biologically meaningful: tau is an intrinsically disordered protein, meaning it lacks a stable three-dimensional structure in its normal, soluble state. This disordered nature is precisely what allows tau to flexibly bind microtubules and respond to regulatory phosphorylation, but it also makes tau vulnerable to pathological misfolding. When tau becomes hyperphosphorylated or carries disease-causing mutations, it can transition from this disordered state into structured, beta-sheet-rich aggregates that form the core of neurofibrillary tangles [3][5]. The N279K substitution, by introducing an additional positive charge in a region critical for microtubule binding, likely disrupts normal tau-microtubule interactions and may promote pathological conformational changes.

Recent research has identified multiple pathological tau species beyond full-length protein, including N-terminal truncated forms and acetylated variants that show functional relevance in Alzheimer's disease [3][4]. Studies using patient-derived neurons carrying MAPT mutations reveal early changes in axon development and altered tau phosphorylation patterns, suggesting disease-causing variants disrupt tau function during neuronal maturation long before tangle formation [2]. Advanced cellular models, including cerebral organoids with CRISPR-edited tau phosphorylation sites, demonstrate that both neuronal and astrocytic tau contribute to soluble phospho-tau biomarkers now used clinically to track Alzheimer's progression [5].

The pathogenic classification, population absence, and location within the microtubule-binding domain collectively indicate N279K represents a high-confidence disease-causing variant. While the low structural confidence score reflects tau's intrinsic disorder rather than modeling failure, it underscores the challenge of predicting how specific mutations alter the conformational landscape of disordered proteins. Future experimental studies using patient-derived neurons or engineered organoid models would be valuable to directly measure how N279K affects tau phosphorylation, microtubule binding, aggregation kinetics, and neuronal function [2][5][6].

## Works Cited

[1] Robinson et al. (2026). Idiotypic-susceptible Alzheimer's disease: a clinically relevant, neurofibrillary tangle subtype. Acta neuropathologica. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42069798/)

[2] Mohl et al. (2026). Multi-omic phenotyping of MAPT V337M neurons reveals early changes in axonogenesis and tau phosphorylation. NPJ dementia. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42046563/)

[3] Guedjdal et al. (2026). N-terminally acetylated Met11-Tau: a new pathological truncated Tau species with functional relevance in Alzheimer's disease. Translational neurodegeneration. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42046086/)

[4] Honey et al. (2026). An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degeneration. Nature medicine. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41986736/)

[5] Zhang et al. (2026). Engineered Alzheimer Organoids Validate the Link Between Intracellular and Soluble p-Tau Biomarkers and Highlight the Contribution of Astrocytic Tau. Neuroscience bulletin. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41964788/)

[6] Chen et al. (2026). Study on the improvement effect and mechanism of resveratrol on cognitive impairment in tau mutant adenovirus-induced alzheimer's disease model mice. Psychopharmacology. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42089987/)


## Similar Research

**Biomarker discovery in Alzheimer's and neurodegenerative diseases using Nucleic Acid Linked Immuno-Sandwich Assay.**
Ashton et al. (2025)
*Relevant to Alzheimer's disease research*
[Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40401628/)

**Proteomic analysis reveals distinct cerebrospinal fluid signatures across genetic frontotemporal dementia subtypes.**
Sogorb-Esteve et al. (2025)
*Relevant to Alzheimer's disease research*
[Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/39908349/)

**Protein quality control systems in neurodegeneration - culprits, mitigators, and solutions?**
Ciechanover et al. (2025)
*Relevant to Alzheimer's disease research*
[Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40969213/)

**Melatonin-Mediated Nrf2 Activation as a Potential Therapeutic Strategy in Mutation-Driven Neurodegenerative Diseases.**
Inigo-Catalina et al. (2025)
*Relevant to Alzheimer's disease research*
[Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41154499/)

**Alzheimer's Disease Continuum: Evaluating the Relationship between Fluid Biomarkers and Patients' Phenotype and Profile.**
Gerlando et al. (2026)
*Relevant to Alzheimer's disease research*
[Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41619269/)

---

## Clinical Data

### ClinVar
- **Classification:** Pathogenic
- **Review Status:** criteria provided, multiple submitters
- **Last Evaluated:** 2026-01-01

### gnomAD

Not found in gnomAD.

---

## Open Targets Disease Associations

| Disease | Score | Data Sources |
|---------|-------|--------------|
| Pick disease | 0.760 | literature, animal_model, genetic_association, genetic_literature |
| frontotemporal dementia | 0.736 | literature, genetic_association |
| supranuclear palsy, progressive, 1 | 0.735 | literature, genetic_association, genetic_literature |
| Atypical progressive supranuclear palsy | 0.723 | animal_model, genetic_association, genetic_literature |
| Progressive supranuclear palsy - parkinsonism | 0.722 | literature, genetic_association, genetic_literature |
| Classical progressive supranuclear palsy | 0.717 | literature, genetic_association, clinical, genetic_literature |
| progressive supranuclear palsy | 0.708 | literature, genetic_association, genetic_literature, clinical |
| progressive supranuclear palsy-parkinsonism syndrome | 0.655 | literature, genetic_association, genetic_literature |
| semantic dementia | 0.651 | literature, animal_model, genetic_association, genetic_literature |
| late-onset Parkinson disease | 0.632 | literature, genetic_association, genetic_literature |

*...and 1172 more associations*

---

## AI Research Brief

# Research Brief: TAU N279K Variant

## Pathogenic Mechanisms

The N279K mutation in the TAU (MAPT) protein represents a well-characterized pathogenic variant that fundamentally disrupts tau's primary physiological function. Located within the microtubule-binding domain, this substitution of asparagine to lysine introduces an additional positive charge that significantly reduces tau's affinity for microtubules, thereby impairing its ability to stabilize the neuronal cytoskeleton. This loss of normal function is compounded by a toxic gain-of-function: the N279K variant exhibits enhanced propensity for aberrant aggregation into neurofibrillary tangles, the pathological hallmark of tauopathies. The mutation affects a protein normally involved in critical cellular processes including actin binding, axon development, and amyloid fibril formation. Known interactions with key proteins such as HSP90AB1, GSK3B, and SNCA suggest that the N279K variant may disrupt multiple proteostatic and signaling pathways. The development of strain-specific diagnostic assays has advanced our understanding of how different tau variants, including N279K, may propagate distinct pathological conformations throughout the brain.

## Clinical Significance

N279K is definitively classified as pathogenic and serves as a causative mutation for frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), not Alzheimer's disease. This distinction is clinically important, as the mutation results in a more aggressive disease course than typical late-onset tauopathies. Carriers typically develop symptoms in their 40s-50s, presenting with rapid cognitive decline accompanied by prominent movement disorders characteristic of parkinsonism. The early age of onset and rapid progression distinguish N279K from sporadic tauopathies and underscore the severe functional consequences of this single amino acid substitution. The variant's location in the microtubule-binding domain directly correlates with both loss of cytoskeletal stabilization function and gain of aggregation propensity, creating a dual pathogenic mechanism that drives neurodegeneration.

## Therapeutic Landscape

Current therapeutic approaches for N279K-associated tauopathy remain largely supportive, though recent research has identified promising intervention strategies. The identification of specific kinase targets involved in tau-related synaptic dysfunction offers potential for developing targeted pharmacological interventions that could slow disease progression. Given the aggregation-prone nature of the N279K variant, therapeutic strategies targeting tau assembly and propagation represent rational approaches. The mutation's effect on reducing microtubule binding while promoting aggregation suggests that compounds stabilizing the tau-microtubule interaction or preventing pathological tau conformations could have therapeutic benefit. Strain-specific diagnostic assays now enable better patient stratification and monitoring of potential therapeutic responses, though no disease-modifying treatments specific to N279K currently exist in clinical use.

## Research Directions

Critical knowledge gaps remain regarding the precise molecular mechanisms by which the N279K substitution promotes tau aggregation and the specific conformational changes it induces. Structural characterization using techniques like AlphaFold modeling (9 structures currently available) should be integrated with experimental validation to understand how this charge substitution alters tau's conformational landscape. Future research should focus on: (1) developing N279K-specific biomarkers for early disease detection in at-risk families; (2) investigating whether kinase inhibitors targeting GSK3B or other tau-modifying enzymes can prevent aggregation or restore function; (3) exploring the role of HSP90AB1 and other chaperone proteins in managing mutant tau proteostasis; and (4) establishing whether therapies effective against other tau variants show cross-reactivity with N279K pathology. Given the monogenic nature of this variant, N279K carriers represent an ideal population for clinical trials of emerging tau-targeted therapies, potentially providing proof-of-concept for broader tauopathy interventions.

---

## Agent Findings

### Literature (1)
- **2026-05-12:** These papers provide important insights into tau N279K pathology through advanced detection methods and mechanistic understanding. The salt-modulated RT-QuIC assay offers a novel diagnostic approach for distinguishing N279K tau aggregates, while the kinase inhibitor studies suggest potential therapeutic interventions targeting the underlying molecular pathways affected by this variant.

### Clinical (1)
- **2026-05-12:** The N279K mutation in the TAU protein represents the initial data collection point for studying a pathogenic variant that causes frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), not Alzheimer's disease specifically. This baseline measurement is clinically significant because the N279K substitution occurs in the microtubule-binding domain of tau, reducing its ability to bind and stabilize microtubules while increasing tau aggregation into neurofibrillary tangles. Establishing baseline data for this variant is essential for tracking disease progression and developing targeted therapies, as carriers typically develop symptoms in their 40s-50s with rapid cognitive decline and movement disorders.

### Structural (1)
- **2026-05-13:** AlphaFold structure update: Baseline check: 9 structure(s) found

### Synthesis (1)
- **2026-05-13:** Synthesis of 1 findings (peptides): The TAU N279K variant associated with Alzheimer's disease shows promising therapeutic potential base...

---

*Generated by [Clarity Protocol](https://clarityprotocol.io)*

**Data Sources:**
- Structure predictions: AlphaFold via ColabFold
- Clinical variant data: ClinVar, gnomAD
- Disease associations: Open Targets Platform
- Research findings: AI agents (PubMed, clinical databases)